Nottingham attack families ask Streeting for names of staff who treated killer
The families of the Nottingham attack victims said they have told the Health Secretary they want the names of staff involved in treating killer Valdo Calocane to be made public.
A February report into the care received by Calocane detailed how he was not forced to have long-lasting antipsychotic medication because he did not like needles, and how other patients at Nottinghamshire Healthcare NHS Foundation Trust also went on to commit 'extremely serious' acts of violence.
The relatives of 19-year-old students Grace O'Malley-Kumar and Barnaby Webber, and 65-year-old caretaker Ian Coates, met with Wes Streeting on Monday and asked for those responsible to be held accountable.
After the meeting, Dr Sanjoy Kumar, Grace's father, said: 'It was the actions of a few people that put a dangerous man out in the community'.
Calocane, who had been diagnosed with paranoid schizophrenia, killed three people and attempted to kill three more in Nottingham in June 2023.
He was sentenced to an indefinite hospital order in January 2024 after admitting manslaughter by diminished responsibility and attempted murder.
Calocane was admitted to hospital and sectioned under the Mental Health Act four times between 2020 and 2022 because of his violent behaviour and refusal to take his medication, before NHS services lost track of him and discharged him in the months before the attacks.
Three reports: including one by the Care Quality Commission (CQC); described failings in his care but none included practitioners' names, Dr Kumar said with copies of the documents in-hand.
Speaking outside the Department for Health and Social Care (DHSC), he told reporters: 'We'd like to know who was involved in the care of this person who committed all this harm. Why aren't there any names?
'He was sectioned four times – was it four different consultants? Was it one consultant? Who were the teams who didn't do their jobs?'
He said: 'I think we deserve to know the detail – everyone in the country who has suffered the way we have through mental health-related homicide deserves to have the detail.
'When an operation goes wrong, someone gets named.'
Dr Kumar added: 'We want people to just know, if they did wrong, what is it they need to do to be put right? Whether it's retraining, whether it's … doing the professional development again.
'The point is that you just can't have people who are providing a risky service even now.'
He added that the Health Secretary was 'very much on our side, he very much wants to see a way through' and that Mr Streeting has promised 'he's going to work hard at it'.
Prior to the meeting, the families said in a statement that their correspondence with the mental health trust's chief executive, Ifti Majid, had been 'light on detail, vague, evasive, defensive and contradictory'.
They added that he failed to answer Dr Kumar's questions.
Dr Kumar said he has given Mr Streeting the questions he put to the chief executive.
He said the Health Secretary 'has promised to do his best to get us all the answers', adding that he has confidence in Mr Streeting because he has 'taken a personal interest in this case' and likewise 'wants to end homicide by mental health'.
Their meeting also follows a complaint lodged with the Independent Office for Police Conduct (IOPC) by the families regarding an 'offensive' encounter with one of the watchdog's regional directors.
Dr Kumar told The Sunday Times newspaper that their meeting with the IOPC, nine months after the attacks, began with a prayer, which he found 'patronising'.
The issue was not discussed with Mr Streeting on Monday and would require a different meeting, he told reporters.
A DHSC spokesperson said: 'Nottinghamshire Healthcare NHS Foundation Trust and NHS England have accepted all the recommendations made in both the CQC and NHS England-commissioned reviews into the care and treatment received by Valdo Calocane.
'The Health and Social Care Secretary has called for recommendations from both reviews to be implemented as soon as possible and met with the bereaved families today to discuss the NHS England-commissioned Independent Homicide Review.
'As part of this work, NHS England has developed and is actively implementing evidence-based national guidance, so that all trusts are clear on the standards of care expected for patients with serious mental illnesses.
'We remain committed to delivering the fundamental changes needed to mental health services to prevent similar tragedies from occurring in the future.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Yahoo
10 hours ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Yahoo
16 hours ago
- Yahoo
MPs may have passed the assisted dying bill, but the debate is just beginning
Now that the assisted dying bill has passed its momentous third reading in the House of Commons, it may seem like legalisation in England and Wales is a done deal. But despite this significant milestone, the bill is not yet law and its journey through the House of Lords is far from a formality. While the terminally ill adults (end of life) bill is now closer than ever to becoming law, both the Commons and the Lords must agree on its final wording. And just like in the Commons, there are passionate supporters and vocal opponents in the Lords. Peers are expected to focus their attention on a number of outstanding, and controversial, issues. One of the biggest concerns that surfaced during both the report stage and today's third reading relates to the speed and process of drafting the legislation. Because this is a private member's bill, introduced by Labour MP Kim Leadbeater, it was subject to strict timelines. Leadbeater had just 85 days to work with legal drafters and set out a policy framework before the bill was published ahead of its second reading in November 2024. Despite this, the democracy-supporting charity the Hansard Society has noted that the bill is 'among the most heavily scrutinised in recent times', and it could ultimately receive up to 200 hours of parliamentary debate, especially now that it has moved to the Lords. Still, the fast turnaround meant that many important decisions, such as what medications will be approved for use in assisted dying, have been left for the secretary of state to determine later through what's known as delegated legislation (secondary laws made without a full parliamentary vote). One area likely to receive particular scrutiny is the bill's inclusion of so-called 'Henry VIII clauses'. These are controversial powers that allow ministers to make changes to existing primary legislation, effectively altering acts of parliament without needing a new law. A key example is clause 38 that would let ministers revise the NHS Act 2006 to formally include assisted dying within NHS services. Several amendments aimed at strengthening the bill's safeguards were supported during the Commons stages. These included the introduction of independent advocates, a new disability advisory board, and additional protections for people with learning disabilities, mental health conditions, or autism. An amendment from Labour MP Naz Shah was also supported at the third reading, ensuring that a person who chooses to stop eating and drinking will not automatically be considered terminally ill. This is a protection designed to prevent the system being used inappropriately. Yet despite these measures, concerns remain. Critics worry about the risk of coercion, both from others and self imposed. There is particular unease about people feeling pressured to choose assisted dying because they consider themselves a burden. Questions have also been raised about whether those with conditions like anorexia might qualify for assisted dying under the current wording of the bill. Even with the new safeguards, including mandatory training for doctors to detect coercion and assess mental capacity, many feel the bill needs tighter definitions and clearer criteria to protect the most vulnerable. The impact on palliative and end-of-life care continues to be a major point of debate. Today, MPs backed an amendment from Liberal Democrat MP Munira Wilson that would require the government to assess the state of palliative care services within one year of the law being enacted. Peers in the House of Lords may push further on this issue. Some may argue that before a person can request assisted dying, they should first be referred to a palliative care specialist to fully understand their options. Others may want the law to spell out more clearly who is qualified to assess these requests. Another key question is who should provide assisted dying services. The British Medical Association has previously suggested a model where assisted dying operates outside the core NHS system. This would be a kind of parallel service overseen by the health secretary but delivered by independent providers. This would be similar to how early medical abortions are offered in some parts of the UK. Time is tight in the Lords, so peers will probably focus on a few high priority areas. Any amendments will need to be proposed, debated and approved quickly if the bill is to continue progressing this session. Even if the bill passes, it includes a four year implementation period to allow for the development of more detailed policies, including training for professionals, protocols for medication and clearer guidance on safeguarding. The passing of the bill in the Commons is historic. But the national conversation on assisted dying is not over. And the next phase will determine how this sensitive and deeply personal issue is handled in practice. This article is republished from The Conversation under a Creative Commons license. Read the original article. Suzanne Ost has previously received funding from the AHRC for her assisted dying research. Nancy Preston receives funding from Horizon Europe, Horizon 2020 and the NIHR
